|
2.
|
|
12 p, 506.4 KB |
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
/
Stein, Eytan M. (Memorial Sloan Kettering Cancer Center (New York)) ;
DeAngelo, Daniel J. (Dana-Farber Cancer Institute (Boston, Massachusetts)) ;
Chromik, Jörg (Goethe University Frankfurt) ;
Chatterjee, Manik (University Hospital of Würzburg) ;
Bauer, Sebastian (German Consortium of Translational Cancer Research (DKTK)) ;
Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan)) ;
Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ;
de Vos, Filip (University Medical Center Utrecht) ;
Steeghs, Neeltje (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Cassier, Philippe A. (Léon Bérard Center) ;
Tai, David (National Cancer Center Singapore) ;
Kiladjian, Jean-Jacques (Université de Paris) ;
Yamamoto, Noboru (National Cancer Center Hospital (Tokyo, Japó)) ;
Mous, Rogier (University Medical Center Utrecht) ;
Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Minami, Hironobu (Kobe University Graduate School of Medicine and Hospital (Japó)) ;
Ferretti, Stephane (Novartis Institutes for Biomedical Research) ;
Guerreiro, Nelson (Novartis Institutes for Biomedical Research) ;
Meille, Christophe (Novartis Institutes for Biomedical Research) ;
Radhakrishnan, Rajkumar (Novartis Healthcare Private Limited (Hyderabad, India)) ;
Pereira, Bernard (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ;
Mariconti, Luisa (Novartis Institutes for Biomedical Research) ;
Halilovic, Ensar (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ;
Fabre, Claire (Novartis Institutes for Biomedical Research) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
This phase I, dose-escalation study investigated the recommended dose for expansion (RDE) of siremadlin, a p53-MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers. Initial dosing regimens were: 1A (day 1; 21-day cycle; dose 12. [...]
2021 -  10.1158/1078-0432.CCR-21-1295
Clinical Cancer Research, Vol. 28 (december 2021) , p. 870-881
|
|
|
3.
|
|
11 p, 900.3 KB |
Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors
/
Lewis, James H. (MedStar Georgetown University Hospital) ;
Gelderblom, Hans J (Leiden University Medical Center) ;
van de Sande, Michiel (Leiden University Medical Center (Països Baixos)) ;
Stacchiotti, Silvia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Healey, John H. (Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College (Nova York, Estats Units d'Amèrica)) ;
Tap, William D. (Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College (Nova York, Estats Units d'Amèrica)) ;
Wagner, Andrew J. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Druta, Mihaela (Moffitt Cancer Center (Tampa, Florida)) ;
Lin, ChiaChi Chi Josh (National Taiwan University Hospital (Taipei, Taiwan)) ;
Baba, Hideo Andreas (University Hospital Essen (Alemanya)) ;
Choi, Youngsook (Daiichi Sankyo. Inc (Nova Jersey, Estats Units)) ;
Wang, Qiang (Daiichi Sankyo. Inc (Estats Units)) ;
Shuster, Dale E. (Daiichi Sankyo. Inc (Estats Units))) ;
Bauer, Sebastian (University of Duisburg-Essen (Alemanya))
Background: Pexidartinib is approved in the U. S. for tenosynovial giant cell tumors (TGCTs). Herein, we assessed the hepatic safety profile of pexidartinib across patients with TGCTs receiving pexidartinib. [...]
2021 - 10.1002/onco.13629
The Oncologist, Vol. 26 Núm. 5 (may 2021) , p. e863-e873
|
|
|
4.
|
|
14 p, 2.6 MB |
Epithelioid hemangioendothelioma, an ultra-rare cancer : a consensus paper from the community of experts
/
Stacchiotti, Silvia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Miah, Aisha B. (The Royal Marsden Hospital) ;
Frezza, Anna Maria (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Messiou, Christina (Department of Radiology. The Royal Marsden Hospital and The Institute of Cancer Research) ;
Morosi, Carlo (Radiology Department. Fondazione IRCCS Istituto Nazionale Tumori) ;
Caraceni, Augusto (Fondazione IRCCS Istituto Nazionale Tumori) ;
Antonescu, Cristina (Memorial Sloan Kettering Cancer Center) ;
Bajpai, Jyoti (Homi Bhabha National Institute. Medical Oncology Department) ;
Baldini, Elizabeth Healey (Dana-Farber Cancer Center/Brigham) ;
Bauer, Sebastian (University of Duisburg-Essen) ;
Biagini, Roberto (Regina Elena National Cancer Institute) ;
Bielack, Stefan S. (Klinikum Stuttgart - Olgahospital) ;
Blay, Jean-Yves (Department of Medical Oncology. Centre Leon Berard. Université Claude Bernard Lyon. Unicancer) ;
Bonvalot, Sylvie (Institut Curie. Department of Surgical Oncology) ;
Boukovinas, Ioannis P. (Nordix) ;
Bovee, Judith V.M.G. (Leiden University Medical Center) ;
Boye, Kjetil (The Norwegian Radium Hospital) ;
Brodowicz, Thomas (Medical University Vienna) ;
Callegaro, Dario (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
De Álava, Enrique (Department of Normal and Pathological Cytology and Histology. School of Medicine. University of Seville) ;
Deoras-Sutliff, M. (The EHE Foundation) ;
Dufresne, Armelle (Department of Medical Oncology. Centre Leon Berard. Université Claude Bernard Lyon. Unicancer) ;
Eriksson, Mikael (Department of Oncology. Skane University Hospital and Lund University) ;
Errani, Costantino (Orthopaedic Service. Musculoskeletal Oncology Department. IRCCS Istituto Ortopedico Rizzoli) ;
Fedenko, Alexander (Medical Oncology Division. P.A. Herzen Cancer Research Institute) ;
Ferraresi, Virginia (Sarcomas and Rare Tumors Unit. IRCCS Regina Elena National Cancer Institute) ;
Ferrari, Andrea (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Fletcher, Christopher D.M. (Department of Pathology Brigham & Women's Hospital) ;
Garcia del Muro, Xavier (Universitat de Barcelona) ;
Gelderblom, Hans J. (Department of Medical Oncology. Leiden University Medical Center) ;
Gladdy, Rebecca A. (University of Toronto and Lunenfeld-Tanenbaum Research Institute) ;
Gouin, François (Department of Surgery. Centre Leon Berard) ;
Grignani, Giovanni (Candiolo Cancer Institute. FPO - IRCCS) ;
Gutkovich, J. (NUY Langone Medical Center) ;
Haas, Rick (Department of Radiotherapy. the Leiden University Medical Center) ;
Hindi, Nadia (Universidad de Sevilla. Instituto de Biomedicina de Sevilla) ;
Hohenberger, Peter (Mannheim University Medical Center) ;
Huang, Paul (Division of Molecular Pathology. The Institute of Cancer Research) ;
Joensuu, Heikki T. (Department of Oncology. Helsinki University Hospital & Helsinki University) ;
Jones, Robin Lewis (Department of Cancer. The Royal Marsden Hospital and The Institute of Cancer Research) ;
Jungels, Christiane (Institut Jules Bordet. Université Libre de Bruxelles) ;
Kasper, Bernd (University of Heidelberg. Mannheim University Medical Center. Sarcoma Unit) ;
Kawai, Akira (Musculoskeletal Oncology and Rehabilitation Medicine. Rare Cancer Center National Cancer Center Hospital) ;
Le Cesne, Axel (International Department. Gustave Roussy) ;
Le Grange, Franél (UCLH - University College London Hospitals NHS Foundation Trust) ;
Leithner, Andeas (Department of Orthopaedics and Trauma Medical University Graz) ;
Leonard, H. (Chair of Trustees of the EHE Rare Cancer Charity (UK). Charity number 1162472) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Martin Broto, Javier (Hospital Universitario Fundación Jiménez Díaz) ;
Merimsky, Ofer (Unit of Soft Tissue and Bone Oncology. Division of Oncology. Tel-Aviv Medical Center affiliated with Sackler School of Medicine. Tel Aviv University) ;
Merriam, Priscilla (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Department of Medical Oncology) ;
Miceli, Rosalba (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Mir, Olivier (Sarcoma Group. Gustave Roussy) ;
Molinari, Massimo (University of Pittsburgh Medical Center. Thomas Starzl Transplant Institute) ;
Montemurro, Michael (Oncology. CHUV Lausanne) ;
Oldani, Graziano (Division of Abdominal Surgery. University Hospitals of Geneva) ;
Palmerini, Emanuela (Chemotherapy Unit. IRCCS Istituto Ortopedico Rizzoli) ;
Pantaleo, Maria Abbondanza. (Division of Oncology. IRCCS Azienda Ospedaliero-Universitaria di Bologna) ;
Patel, Sapna Pradyuman (Sarcoma Center. The University of Texas M.D. Anderson Cancer Center) ;
Piperno-Neumann, Sophie (Department of Medical Oncology. Institut Curie) ;
Raut, Chandrajit Premanand (Dana Farber Cancer Center. Harvard Medical School) ;
Ravi, Vinod (Sarcoma Center. The University of Texas M.D. Anderson Cancer Center) ;
Razak, Albiruni Ryan Abdul (Princess Margaret Cancer Centre and Sinai Healthcare System & Faculty of Medicine. University of Toronto) ;
Reichardt, Peter (Helios Klinikum Berlin-Buch. Department of Oncology and Palliative Care) ;
Rubin, Brian P. (Robert J. Tomsich Pathology and Laboratory Medicine Institute. Cleveland Clinic) ;
Rutkowski, Piotr (Maria Sklodowska-Curie National Research Institute of Oncology. Department of Soft Tissue/Bone Sarcoma and Melanoma) ;
Safwat, Akmal Ahmed (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Sangalli, Claudia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Sapisochin, Gonzalo (Multi-Organ Transplant and HPB Surgical Oncology. Division of General Surgery. Department of Surgery. University of Toronto) ;
Sbaraglia, Marta (Department of Pathology. Azienda Ospedaliera Università Padova) ;
Scheipl, Susanne (Department of Orthopaedics and Trauma. Medical University of Graz) ;
Schöffski, Patrick (Leuven Cancer Institute) ;
Strauss, Dirk Cornelius (Department of Surgery. The Royal Marsden Hospital and The Institute of Cancer Research) ;
Strauss, Sandra J. (University College London Hospital) ;
Sundby Hall, Kirsten (Department of Oncology. Oslo University Hospital. The Norwegian Radium Hospital) ;
Tap, William D. (Department of Medicine. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College) ;
Trama, Annalisa (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Tweddle, A. (Palliative Care. The Royal Marsden Hospital and The Institute of Cancer Research London) ;
van der Graaf, Winette T.A. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
van de Sande, Michiel (Department of Orthopedic Surgery Bone and Soft Tissue Tumor Unit. Leiden University Medical Center) ;
Van Houdt, Winan (Sarcoma and Melanoma Unit. The Netherlands Cancer Institute) ;
van Oortmerssen, Gerard (Co-Chair of Sarcoma Patients EuroNet (SPAEN). Woelfersheim. Germany & Chairman of the Dutch organisation for sarcoma patients (Patiëntenplatform Sarcomen). Guest researcher at Leiden University (Leiden Institute for Advanced Computer Science). Leiden University) ;
Wagner, Andrew J. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Department of Medical Oncology) ;
Wartenberg, Markus (Chair of the Board of Directors of Sarcoma Patients EuroNet (SPAEN). Sarcoma Patients EuroNet (SPAEN)) ;
Wood, J. (The Royal Marsden NHS Foundation Trust) ;
Zaffaroni, Nadia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Zimmermann, Camilla (Department of Supportive Care. Princess Margaret Cancer Centre and Division of Palliative Medicine. Department of Medicine. University of Toronto) ;
Casali, Paolo Giovanni (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Dei Tos, Angelo (Department of Pathology. Azienda Ospedaliera Università Padova) ;
Gronchi, Alessandro (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia))
Epithelioid hemangioendothelioma (EHE) is an ultra-rare, translocated, vascular sarcoma. EHE clinical behavior is variable, ranging from that of a low-grade malignancy to that of a high-grade sarcoma and it is marked by a high propensity for systemic involvement. [...]
2021 - 10.1016/j.esmoop.2021.100170
ESMO open, Vol. 6 Núm. 3 (june 2021) , p. 100170
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
